News & events Upcoming events MedLab Middle East 2022 Jan 24, 2022 - Jan 27, 2022 Dubai , United Arab Emirates More info and meet us there AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's diseases and related neurological disorders Mar 15, 2022 - Mar 20, 2022 Barcelona , Spain More info and meet us there 19th CACLP (China Association of Clinical Laboratory Practice) Expo Mar 27, 2022 - Mar 29, 2022 Nanchang , China More info and meet us there See all upcoming events Latest news OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform Dec 8, 2020 Gent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they... Read more Fujirebio Diagnostics Files 510(k) With FDA for Lumipulse® G β-Amyloid Ratio (1-42/1-40) In Vitro Diagnostic Test Dec 2, 2020 —When Cleared, FDA-Designated Breakthrough Device Expected to Be a Commercially Available In Vitro Diagnostic for Patients Being Evaluated... Read more Fujirebio Europe and CENTOGENE enter partnership to provide rapid and high-quality preventive SARS-CoV-2 antigen testing Nov 9, 2020 Gent, Belgium, Cambridge, Mass., USA, and Rostock and Berlin, Germany – November 9, 2020: Fujirebio Europe and Centogene N.V. (Nasdaq: CNTG)... Read more Fujirebio Europe enters an agreement with ADx NeuroSciences for the commercialization of novel biomarkers Sep 4, 2020 Fujirebio Europe and ADx NeuroSciences announced today that they have concluded an agreement related to the development and... Read more Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 antigen assay and the rapid antigen device ESPLINE® SARS-CoV-2 Aug 11, 2020 With these new products Fujirebio further positions itself as a leading global provider of immunoassay testing solutions to the IVD industry... Read more Fujirebio Europe launches the Lumipulse® G Aldosterone and Renin assays for fully automated quantitative determination of aldosterone and active renin Jul 1, 2020 Fujirebio Europe announces the release of the Lumipulse G Aldosterone and Renin assays for the fully automated quantitative determination of... Read more Load More
MedLab Middle East 2022 Jan 24, 2022 - Jan 27, 2022 Dubai , United Arab Emirates More info and meet us there
AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's diseases and related neurological disorders Mar 15, 2022 - Mar 20, 2022 Barcelona , Spain More info and meet us there
19th CACLP (China Association of Clinical Laboratory Practice) Expo Mar 27, 2022 - Mar 29, 2022 Nanchang , China More info and meet us there
OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform Dec 8, 2020 Gent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they... Read more
Fujirebio Diagnostics Files 510(k) With FDA for Lumipulse® G β-Amyloid Ratio (1-42/1-40) In Vitro Diagnostic Test Dec 2, 2020 —When Cleared, FDA-Designated Breakthrough Device Expected to Be a Commercially Available In Vitro Diagnostic for Patients Being Evaluated... Read more
Fujirebio Europe and CENTOGENE enter partnership to provide rapid and high-quality preventive SARS-CoV-2 antigen testing Nov 9, 2020 Gent, Belgium, Cambridge, Mass., USA, and Rostock and Berlin, Germany – November 9, 2020: Fujirebio Europe and Centogene N.V. (Nasdaq: CNTG)... Read more
Fujirebio Europe enters an agreement with ADx NeuroSciences for the commercialization of novel biomarkers Sep 4, 2020 Fujirebio Europe and ADx NeuroSciences announced today that they have concluded an agreement related to the development and... Read more
Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 antigen assay and the rapid antigen device ESPLINE® SARS-CoV-2 Aug 11, 2020 With these new products Fujirebio further positions itself as a leading global provider of immunoassay testing solutions to the IVD industry... Read more
Fujirebio Europe launches the Lumipulse® G Aldosterone and Renin assays for fully automated quantitative determination of aldosterone and active renin Jul 1, 2020 Fujirebio Europe announces the release of the Lumipulse G Aldosterone and Renin assays for the fully automated quantitative determination of... Read more
